Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.97M | -22.67M | -21.15M | -19.12M | -17.12M |
| Total Depreciation and Amortization | 410.30K | 418.60K | 422.00K | 422.00K | 423.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.50M | 1.22M | 921.10K | 877.30K | 836.80K |
| Change in Net Operating Assets | 2.52M | 2.63M | 2.72M | 2.63M | 2.55M |
| Cash from Operations | -19.53M | -18.40M | -17.09M | -15.19M | -13.31M |
| Capital Expenditure | -149.20K | -117.10K | -84.30K | -50.90K | -17.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -149.20K | -117.10K | -84.30K | -50.90K | -17.10K |
| Total Debt Issued | -- | -- | -- | 826.00K | 1.65M |
| Total Debt Repaid | -318.00K | -349.00K | -380.00K | -669.00K | -958.00K |
| Issuance of Common Stock | 29.34M | 27.66M | 25.98M | 24.34M | 22.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.07M | -1.72M | -1.38M | -1.39M | -1.40M |
| Cash from Financing | 19.49M | 18.50M | 17.41M | 16.59M | 15.83M |
| Foreign Exchange rate Adjustments | -2.40K | 138.10K | 274.90K | 429.80K | 589.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -198.10K | 121.00K | 513.70K | 1.78M | 3.10M |